View Cart  

Keep Exchange of Science-Based Information on Off-Label Uses Open, Drugmakers Tell FDA

A A
Biopharma companies should be allowed to provide factual, non-misleading information about their products’ uses in an open, scientific dialogue whether uses are off-label or not, drugmakers are telling the FDA.

To View This Article:

Login

Subscribe To Drug Industry Daily